RenovoRx Inc - RNXT STOCK NEWS

RenovoRx highlights the recent presentation of clinical data abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting. The sub-study of the pivotal Phase III TIGeR-PaC clinical trial provides important data for optimizing TAMP therapy in patients with locally advanced pancreatic cancer.

RenovoRx closes an $11.1 million private placement, bringing the total gross proceeds to $17.2 million since the beginning of 2024. The funding will support pivotal Phase III clinical trials and expand the development pipeline into additional cancer indications, ensuring financial stability until 2026.

RenovoRx secures $11.1 million in private placement financing to extend cash runway into 2026. The funding will support the pivotal Phase III TIGeR-PaC trial and expand the TAMP clinical development pipeline into additional cancer indications.

RenovoRx, Inc. (RNXT) CEO to present at Canaccord Genuity 2024 Horizons in Oncology Virtual Conference to discuss positive interim analysis in pivotal Phase III TIGeR-PaC clinical trial for RenovoGem™ in locally advanced pancreatic cancer. Recent private placement extended cash runway for key milestones in 2024.

RenovoRx, Inc. (RNXT) announced CEO Shaun Bagai will present at the 36th Annual ROTH Conference to discuss positive interim analysis results for the pivotal Phase III TIGeR-PaC clinical trial on RenovoGem™ for pancreatic cancer. The company also completed a $6.1 million private placement to extend cash runway for upcoming milestones in 2024.

RenovoRx promotes Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak to Principal Accounting Officer, showcasing commitment to leadership and innovation in precision oncology therapies. Ms. Gentry's new role will focus on clinical operations for RenovoGemTM in Locally Advanced Pancreatic Cancer, while Mr. Kocak will lead financial management and strategic planning.

RenovoRx, Inc. (RNXT) provided a letter to shareholders from CEO Shaun Bagai, highlighting key achievements in 2023 and the company's focus on advancing the development of their proprietary targeted combination therapy platform, Trans-Arterial Micro-Perfusion (TAMP™). The completion of a $6.1 million private placement has extended their cash runway, allowing them to drive towards a second interim analysis for their pivotal Phase III TIGeR-PaC study in late 2024. The study involves their lead product candidate, RenovoGem™, for the treatment of LAPC, utilizing their TAMP administration technology combined with the FDA-approved cancer drug, gemcitabine. RenovoRx also announced a collaboration with Imugene to explore expansion of their TAMP product pipeline with Imugene’s CF33 oncolytic virus therapy for the treatment of difficult-to-access tumors. Additionally, the company filed an additional international patent application under the Patent Cooperation Treaty for their TAMP therapy platform, further bolstering their intellectual property portfolio.

RenovoRx, Inc. has announced the closing of a private placement, resulting in gross proceeds of approximately $6.1 million. The company's management team and Board of Directors participated in the private placement, reflecting their strong belief in the company. The funds will extend RenovoRx’s cash runway as it continues its ongoing pivotal TIGeR-PaC Phase III clinical trial, with a second interim analysis expected in late 2024. The company also plans to use the proceeds to engage additional clinical trial sites for its Phase III CouGar study in bile duct cancer and explore other potential pipeline indication opportunities.

RenovoRx, Inc. (Nasdaq: RNXT) announced the expansion of their clinical development pipeline in preparation for the commencement of the CouGar Trial, a second Phase III trial evaluating RenovoGem in bile duct cancer. The trial aims to evaluate the safety and efficacy of intravenous chemotherapy versus Trans-Arterial Micro-Perfusion via RenovoGem with intravenous durvalumab for unresectable, locally advanced eCCA. The study brings hope for a new treatment option for patients diagnosed with this aggressive cancer, addressing the urgent clinical need for a safe and effective therapy in this important patient population.